KILL Samsung Bioepis Announces Positive Preliminary Phase 1 Data for SB27, Proposed Biosimilar to Keytruda (Pembrolizumab)

via Business Wire
ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.

Samsung Bioepis Co., Ltd. requests that their press release NewsItemId: 20260505353718 “Samsung Bioepis Announces Positive Preliminary Phase 1 Data for SB27, Proposed Biosimilar to Keytruda (Pembrolizumab)” be killed.

The release was issued prematurely by Samsung Bioepis Co., Ltd.

The news release will be updated and redistributed in the near future, incorporating further information on SB27.

We are excited to announce preliminary results from the Phase 1 study for SB27, our pembrolizumab biosimilar candidate. These topline positive results reinforce our scientific expertise and leadership in biosimilar development.

Contacts

Report this content

If you believe this article contains misleading, harmful, or spam content, please let us know.

Report this article